Introduction

Toxins and Hemostasis: From Bench to Bedside

Volumn , Issue , 2011, Pages 1-9

  Clemetson, Kenneth J ^a   Kini, R Manjunatha ^a,b,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920166193     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-9295-3_1     Document Type: Editorial

References (16)

1. Bell, W.R.J., 1997. Defibrinogenating enzymes. Drugs 54 (Suppl. 3), 18-30.
2. Brunner, H.R., Gavras, H., Turini, G.A., Waeber, B., Cappuis, P., McKinstry, D.N., 1978. Longterm treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor. Clin. Sci. Mol. Med. Suppl. 4, 293s-295s.
3. Ferreira, S.H., Rocha e Silva, M., 1965. Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from Bothrops jararaca venom. Experientia 21, 347-349.
4. Fry, B.G., Vidal, N., Norman, J.A., Vonk, F.J., Scheib, H., Ramjan, S.F., Kuruppu, S., Fung, K., Hedges, S.B., Richardson, M.K., Hodgson, W.C., Ignjatovic, V., Summerhayes, R., Kochva, E., 2006. Early evolution of the venom system in lizards and snakes. Nature 439, 584-588.
5. Fry, B.G., Wroe, S., Teeuwisse, W., van Osch, M.J., Moreno, K., Ingle, J., McHenry, C., Ferrara, T., Clausen, P., Scheib, H., Winter, K.L., Greisman, L., Roelants, K., van derWeerd, L., Clemente, C.J., Giannakis, E., Hodgson, W.C., Luz, S., Martelli, P., Krishnasamy, K., Kochva, E., Kwok, H.F., Scanlon, D., Karas, J., Citron, D.M., Goldstein, E.J., McNaughtan, J.E., Norman, J.A., 2009. A central role for venom in predation by Varanus komodoensis (Komodo Dragon) and the extinct giant Varanus (Megalania) priscus. Proc. Natl. Acad. Sci., U.S.A. 106, 8969-8974.
6. Hantgan, R.R., Stahle, M.C., 2009. Integrin priming dynamics: mechanisms of integrin antagonistpromoted αIIbβ3:PAC-1 molecular recognition. Biochemistry 48, 8355-8365.
7. Hartman, G.D., Egbertson, M.S., Halczenko, W., Laswell, W.L., Duggan, M.E., Smith, R.L., Naylor, A.M., Manno, P.D., Lynch, R.J., Zhang, G.X., Chang, C.T.C., Gould, R.J., 1992. Nonpeptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35, 4640-4642.
8. Kaplan, H.R., Cohen, D.M., Essenburg, A.D., Major, T.C., Mertz, T.E., Ryan, M.J., 1984. CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors. Fed. Proc. 43, 1326-1329.
9. Mousa, S.A., Kapil, R., Mu, D.X., 1999. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. Arterioscler. Thromb. Vasc. Biol. 19, 2535-2541.
10. Ofosu, F.A., Fenton, J.W. II., Maraganore, J., Blajchman, M.A., Yang, X., Smith, L., Anvari, N., Buchanan, M.R., Hirsh, J., 1992. Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin. Biochem. J. 283, 893-897.
11. Römisch, J., Stöhr, H.A., Stauss, H., Koschinsky, R., Stüber, W., Pâques, E.P., 1994. Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide. Thromb. Haemost. 71, 320-324.
12. Scarborough, R.M., Rose, J.W., Hsu, M.A., Phillips, D.R., Fried, V.A., Campbell, A.M., Nannizzi, L., Charo, I.F., 1991. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J. Biol. Chem. 266, 9359-9362.
13. Schoni, R., 2005. The use of snake venom-derived compounds for new functional diagnostic test kits in the field of haemostasis. Pathophysiol. Haemost. Thromb. 34, 234-240.
14. Sweet, C.S., Gross, D.M., Arbegast, P.T., Gaul, S.L., Britt, P.M., Ludden, C.T., Weitz, D., Stone, C.A., 1981. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-LPro (MK-421), an orally active converting enzyme inhibitor. J. Pharmacol. Exp. Ther. 216, 558-566.
15. Tcheng, J.E., Harrington, R.A., Kottke-Marchant, K., Kleiman, N.S., Ellis, S.G., Kereiakes, D.J., Mick, M.J., Navetta, F.I., Smith, J.E., Worley, S.J., Miller, J.A., Joseph, D.M., Sigmon, K.N., Kitt, M.M., Dumee, C.P., Califf, R.M., Topol, E.J., 1995. Multicenter, randomized, doubleblind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 91, 2151-2157.
16. Tschudi, M., Lämmle, B., Alberio, L., 2009. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: A single-center experience with 68 patients. Blood 113, 2402-2409.